203 related articles for article (PubMed ID: 23242124)
1. Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease.
Alsadany MA; Shehata HH; Mohamad MI; Mahfouz RG
Am J Alzheimers Dis Other Demen; 2013 Feb; 28(1):54-61. PubMed ID: 23242124
[TBL] [Abstract][Full Text] [Related]
2. Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease.
Pajonk FG; Kessler H; Supprian T; Hamzei P; Bach D; Schweickhardt J; Herrmann W; Obeid R; Simons A; Falkai P; Multhaup G; Bayer TA
J Alzheimers Dis; 2005 Sep; 8(1):23-7. PubMed ID: 16155346
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease.
Rembach A; Doecke JD; Roberts BR; Watt AD; Faux NG; Volitakis I; Pertile KK; Rumble RL; Trounson BO; Fowler CJ; Wilson W; Ellis KA; Martins RN; Rowe CC; Villemagne VL; Ames D; Masters CL; AIBL research group ; Bush AI
J Alzheimers Dis; 2013; 34(1):171-82. PubMed ID: 23168449
[TBL] [Abstract][Full Text] [Related]
4. Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients.
Domínguez RO; Marschoff ER; González SE; Repetto MG; Serra JA
Diabetes Res Clin Pract; 2012 Oct; 98(1):68-74. PubMed ID: 22658669
[TBL] [Abstract][Full Text] [Related]
5. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease.
Kim SM; Song J; Kim S; Han C; Park MH; Koh Y; Jo SA; Kim YY
BMC Neurol; 2011 May; 11():51. PubMed ID: 21569380
[TBL] [Abstract][Full Text] [Related]
6. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
[TBL] [Abstract][Full Text] [Related]
7. Plasma d-glutamate levels for detecting mild cognitive impairment and Alzheimer's disease: Machine learning approaches.
Chang CH; Lin CH; Liu CY; Huang CS; Chen SJ; Lin WC; Yang HT; Lane HY
J Psychopharmacol; 2021 Mar; 35(3):265-272. PubMed ID: 33586518
[TBL] [Abstract][Full Text] [Related]
8. Oxidative Stress Markers and Metal Ions are Correlated With Cognitive Function in Alzheimer's Disease.
Pu Z; Xu W; Lin Y; He J; Huang M
Am J Alzheimers Dis Other Demen; 2017 Sep; 32(6):353-359. PubMed ID: 28554217
[TBL] [Abstract][Full Text] [Related]
9. Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer's Disease.
Jiang T; Tan L; Gao Q; Lu H; Zhu XC; Zhou JS; Zhang YD
Curr Neurovasc Res; 2016; 13(2):96-9. PubMed ID: 26907614
[TBL] [Abstract][Full Text] [Related]
10. Serum Non-Ceruloplasmin Non-Albumin Copper Elevation in Mild Cognitive Impairment and Dementia due to Alzheimer's Disease: A Case Control Study.
Rozzini L; Lanfranchi F; Pilotto A; Catalani S; Gilberti ME; Paganelli M; Apostoli P; Padovani A
J Alzheimers Dis; 2018; 61(3):907-912. PubMed ID: 29332043
[TBL] [Abstract][Full Text] [Related]
11. Elevation of serum copper levels in Alzheimer's disease.
Squitti R; Lupoi D; Pasqualetti P; Dal Forno G; Vernieri F; Chiovenda P; Rossi L; Cortesi M; Cassetta E; Rossini PM
Neurology; 2002 Oct; 59(8):1153-61. PubMed ID: 12391342
[TBL] [Abstract][Full Text] [Related]
12. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
[TBL] [Abstract][Full Text] [Related]
13. Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer's disease.
Meng X; Li T; Wang X; Lv X; Sun Z; Zhang J; Su F; Kang S; Kim S; An SSA; Yu X; Zhang C; Wang H
Alzheimers Res Ther; 2019 Oct; 11(1):89. PubMed ID: 31651358
[TBL] [Abstract][Full Text] [Related]
14. Plasma metals as potential biomarkers in dementia: a case-control study in patients with sporadic Alzheimer's disease.
Xu J; Church SJ; Patassini S; Begley P; Kellett KAB; Vardy ERLC; Unwin RD; Hooper NM; Cooper GJS
Biometals; 2018 Apr; 31(2):267-276. PubMed ID: 29516299
[TBL] [Abstract][Full Text] [Related]
15. Potential blood biomarker for disease severity in the Taiwanese population with Alzheimer's disease.
Huang CW; Wang SJ; Wu SJ; Yang CC; Huang MW; Lin CH; Cheng IH
Am J Alzheimers Dis Other Demen; 2013 Feb; 28(1):75-83. PubMed ID: 23230229
[TBL] [Abstract][Full Text] [Related]
16. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
[TBL] [Abstract][Full Text] [Related]
17. Differences in peripheral oxidative stress markers in Alzheimer's disease, vascular dementia and mixed dementia patients.
Hatanaka H; Hanyu H; Fukasawa R; Hirao K; Shimizu S; Kanetaka H; Iwamoto T
Geriatr Gerontol Int; 2015 Dec; 15 Suppl 1():53-8. PubMed ID: 26671158
[TBL] [Abstract][Full Text] [Related]
18. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
[TBL] [Abstract][Full Text] [Related]
19. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.
Bos I; Vos S; Vandenberghe R; Scheltens P; Engelborghs S; Frisoni G; Molinuevo JL; Wallin A; Lleó A; Popp J; Martinez-Lage P; Baird A; Dobson R; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Bertram L; Ten Kate M; Barkhof F; Zetterberg H; Lovestone S; Streffer J; Visser PJ
Alzheimers Res Ther; 2018 Jul; 10(1):64. PubMed ID: 29980228
[TBL] [Abstract][Full Text] [Related]
20. Copper perturbation in 2 monozygotic twins discordant for degree of cognitive impairment.
Squitti R; Cassetta E; Dal Forno G; Lupoi D; Lippolis G; Pauri F; Vernieri F; Cappa A; Rossini PM
Arch Neurol; 2004 May; 61(5):738-43. PubMed ID: 15148152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
